Printed From BioPortfolio.com
FDA Grants Priority Review to AstraZeneca and Merck’s Lynparza in Metastatic Breast Cancer
10:19 EDT 18 Oct 2017 | Speciality Pharma Journal
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental New Drug Application (sNDA) for the use of LYNPARZA® (olaparib) tablets in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer …
Original Article: FDA Grants Priority Review to AstraZeneca and Merck’s Lynparza in Metastatic Breast Cancer
